您好，欢迎访问北京市农林科学院 机构知识库！
北京市农林科学院机构知识库

全部

  • 全部
  • 标题
  • 学者
  • 机构
  • 关键词

Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma

文献类型： 外文期刊

作者： Qiu, Jinming 1 ; Zhu, Fangge 1 ; Quan, Rong 2 ; Ye, Haoyuan 1 ; Su, Wenting 1 ; Wang, Renxi 1 ; Fu, Yi 1 ;

作者机构： 1.Capital Med Univ, Beijing Inst Brain Disorders, Collaborat Innovat Ctr Brain Disorders, Lab Brain Disorders,Minist Sci & Technol, 10 Xitoutiao Youanmenwai Fengtai Dist, Beijing 100069, Peoples R China

2.Beijing Acad Agr & Forestry Sci, Inst Anim Husb & Vet Med, 9 Shuguang Garden Middle Rd Haidian Dist, Beijing 100097, Peoples R China

期刊名称：ISCIENCE （ 影响因子：4.1； 五年影响因子：4.7 ）

ISSN：

年卷期： 2025 年 28 卷 9 期

页码：

收录情况： SCI

摘要： Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, and EGFRvIII mutation has been associated with treatment resistance and poor prognosis, highlighting the need for more effective therapeutic strategies. We conducted a random-effects Bayesian network meta-analysis to compare the efficacy and safety of treatments for EGFRvIII-positive recurrent GBM (rGBM), evaluating overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Seven clinical trials were included (n = 716). Rindopepimut (Rind) + Bevacizumab (Beva) emerged as the most promising regimen, supported by its OS advantage in randomized trials, consistently favorable OS and PFS trends, top rankings in all three endpoints, and recommendation by clinical guidelines. Safety analysis showed that Rind + Beva had the lowest incidence of all-grade and grade >= 3 AEs. In conclusion, Rind + Beva represent the leading candidate for EGFRvIII-positive rGBM treatment, with the combination of molecular-targeted vaccines and anti-VEGF antibodies offering a promising strategy.

  • 相关文献
作者其他论文 更多>>
置顶
购物车
反馈

© 京ICP备09089781号-29 主办单位：北京市农林科学院

学术资源： 中国农业科学院 农业专业知识服务系统 农科联盟资源共建共享平台 中国农业科技文献与信息服务平台 中国农业期刊集成服务平台